Margetuximab: An active alternative for later-line therapy in patients with HER2-positive advanced breast cancer

MedComm (2020). 2023 Jul 4;4(4):e322. doi: 10.1002/mco2.322. eCollection 2023 Aug.

Yunxiang Zhou^{1

2}, Xiaojia Wang³, Yiding Chen^{1

2}

¹ Department of Breast Surgery and Oncology The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
² Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
³ Department of Breast Medical Oncology The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences Hangzhou Zhejiang China.

No abstract available